Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10241 in advanced solid tumors
NCT02977364Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dalmelitinib in solid tumor (6 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
dalmelitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02977364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977364.